Hyperparathyroidism News and Research

RSS
Hyperparathyroidism is a condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.

In most cases doctors don't know the cause. The vast majority of cases occur in people with no family history of the disorder. Only about 5 percent of cases can be linked to an inherited problem. Familial multiple endocrine neoplasia type 1 is a rare, inherited syndrome that affects the parathyroids as well as the pancreas and the pituitary gland. Another rare genetic disorder, familial hypocalciuric hypercalcemia, is sometimes confused with typical hyperparathyroidism. Each accounts for about 2 percent of primary hyperparathyroidism cases.

In the United States, about 100,000 people develop the disorder each year. Women outnumber men two to one, and risk increases with age. In women 60 years and older, two out of 1,000 will develop hyperparathyroidism each year.
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Paediatric primary hyperparathyroidism in rarely a familial disorder

Paediatric primary hyperparathyroidism in rarely a familial disorder

Chronic heart failure patients with decreased calcitriol may benefit from aggressive supplementation

Chronic heart failure patients with decreased calcitriol may benefit from aggressive supplementation

Many MEN1 tumour types found in children

Many MEN1 tumour types found in children

Tenofovir stems treatment-induced kidney toxicity in HBV-related chronic hepatitis

Tenofovir stems treatment-induced kidney toxicity in HBV-related chronic hepatitis

Hospira launches Paricalcitol Injection

Hospira launches Paricalcitol Injection

Study: Simple blood test could identify people with hypercalcaemia

Study: Simple blood test could identify people with hypercalcaemia

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Calcium, vitamin D supplements may send blood levels too high for some women

Calcium, vitamin D supplements may send blood levels too high for some women

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

US may be losing ground as the leader in biomedical research

US may be losing ground as the leader in biomedical research

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

Study explores advantages of minimally invasive parathyroidectomy for treating hyperparathyroidism

Study explores advantages of minimally invasive parathyroidectomy for treating hyperparathyroidism

Qualigen's FastPack Vitamin D Immunoassay receives FDA clearance

Qualigen's FastPack Vitamin D Immunoassay receives FDA clearance

Investigators report possible missing link necessary to prevent osteoporosis

Investigators report possible missing link necessary to prevent osteoporosis

OPKO reports more than 50% enrollment in phase 3 trial of Rayaldy for treatment of secondary hyperparathyroidism

OPKO reports more than 50% enrollment in phase 3 trial of Rayaldy for treatment of secondary hyperparathyroidism

OPKO Health acquires Cytochroma

OPKO Health acquires Cytochroma

Study shows how hyperparathyroidism affects people of different racial backgrounds

Study shows how hyperparathyroidism affects people of different racial backgrounds

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.